Sugi Predict

Sugi Predict / Compounds / SCHEMBL10841

SCHEMBL10841

SCHEMBL10841

NCCCNCc1ccc(-c2cn3c(=O)cc(-c4ccccc4OC(F)(F)F)[nH]c3nc2=O)cc1

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.36
▸ SCN9A Q15858 2/20 0.33
▸ MC4R P32245 1/20 0.33
▸ MC5R P33032 1/20 0.33
▸ MC3R P41968 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ RORC P51449 2/20 0.33
▸ NAMPT P43490 1/20 0.32
▸ ABL1 P00519 1/20 0.32
▸ MME P08473 1/20 0.32
▸ SCN5A Q14524 1/20 0.32
▸ METTL3 Q86U44 2/20 0.32
▸ EGFR P00533 1/20 0.32
▸ ACHE P22303 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11960638 0.88 BRD4 (0.37) SCN9AMC4RMC5RMC3RSCN5A
SCHEMBL11920 0.88 MC4R (0.37) FFAR1MC4RMC5RMC3RACHE
SCHEMBL11960643 0.87 MC4R (0.32) MC4RMC5RMC3R
SCHEMBL11960637 0.85 PDCD1 (0.37) FFAR1MC4RMC5RMC3R
SCHEMBL11960642 0.83 HDAC1 (0.34) MC4RMC5RMC3R
SCHEMBL11208 0.83 MC4R (0.33) MC4RMC5RMC3R
SCHEMBL14613 0.82 MC4R (0.34) MC4RMC5RMC3R
SCHEMBL20124123 0.81 MC4R (0.32) MC4RMC5RMC3R
SCHEMBL19573483 0.81 MC4R (0.34) MC4RMC5RMC3R
SCHEMBL16687699 0.80 MC4R (0.33) MC4RMC5RMC3R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10259825-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2019-04-16 — — US disclosed
EP-2488532-B1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MELINTA THERAPEUTICS INC (US) 2018-05-09 — — EP disclosed
US-20170320892-A1 Antimicrobial Compounds And Methods Of Making And Using The Same SILICON VALLEY BANK 2017-11-09 — — US disclosed
US-9573962-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2017-02-21 — — US disclosed
US-20150274752-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME SILICON VALLEY BANK 2015-10-01 — — US disclosed
WO-2011047320-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274752-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME LPO, MPO, CAT FFAR1 4436/4885SCN9A 4729/4885MC4R 3103/4885
US-10259825-B2 Antimicrobial compounds and methods of making and using the same LPO, MPO, CAT FFAR1 4436/4885SCN9A 4729/4885MC4R 3103/4885
US-20170320892-A1 Antimicrobial Compounds And Methods Of Making And Using The Same LPO, MPO, CAT FFAR1 4436/4885SCN9A 4729/4885MC4R 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.